Department of Epidemiology and Health Statistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, China.
Department of Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, China.
J Glob Health. 2023 Sep 8;13:04100. doi: 10.7189/jogh.13.04100.
The Systolic Blood Pressure Intervention Trial (SPRINT) from the US and the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial from China have consistently demonstrated clinical benefits from intensive blood pressure (BP) treatment among elderly adults with hypertension. However, we have little data on the generalisability and potential implications of a scale-up of intensive BP treatment to all eligible elderly in the US and China.
We used two nationally representative data sets from China (Health and Retirement Longitudinal Study (CHALRS), 2011-2012) and the US (National Health and Nutrition Examination Survey (NHANES), 2007-2012) and linked them with CHARLS follow-up data (2013) and the National Death Index (1999-2015), respectively. We estimated the percentage, number, and characteristics of elderly (≥60 years old) meeting the STEP and SPRINT eligibility criteria, and deaths that would be prevented or postponed with the implementation of intensive BP treatment.
Among the Chinese adults aged 60 years and over, 38.89% (95% confidence interval (CI) = 36.97-40.84) or 85.39 (95% CI = 81.14-89.64) million subjects met the STEP criteria, and 40.90 million (47.90%) adults were not taking antihypertensive medications. In the US, 23.77% (95% CI = 22.32%-25.28) or 12.46 (95% CI = 11.68-13.24) million elderly were eligible for the SPRINT, and 5.78 million (46.36%) were untreated. Overall, 0.07 (95% CI = 0.06-0.08) million deaths in the US and 0.31 (95% CI = 0.25-0.39) in China would be averted annually if intensive BP treatment was implemented, while 120 000 and 680 000 of hypotension cases would be identified yearly inthe US and China, respectively.
A substantial percentage of Chinese and the US elderly meet the eligibility criteria for STEP and SPRINT. If intensive BP treatment was adopted, 70 000 and 310 000 deaths would be prevented or postponed yearly in the US and China, respectively.
来自美国的收缩压干预试验(SPRINT)和来自中国的老年高血压患者降压治疗策略研究(STEP)试验一致表明,强化血压(BP)治疗可使高血压老年患者获得临床获益。然而,我们对在美国和中国将强化 BP 治疗推广至所有符合条件的老年人的可推广性和潜在影响知之甚少。
我们使用来自中国的两个全国代表性数据集(中国健康与养老追踪调查(CHARLS),2011-2012 年)和来自美国的全国健康和营养检查调查(NHANES),2007-2012 年),并分别将其与 CHARLS 随访数据(2013 年)和国家死亡指数(1999-2015 年)进行链接。我们估计了符合 STEP 和 SPRINT 入选标准的中国 60 岁及以上老年人的百分比、人数和特征,以及实施强化 BP 治疗后可预防或推迟的死亡人数。
在中国 60 岁及以上的成年人中,38.89%(95%置信区间(CI)=36.97-40.84)或 85.39 万人(95% CI=81.14-89.64)符合 STEP 标准,40.90 万人(47.90%)未服用抗高血压药物。在美国,23.77%(95% CI=22.32%-25.28)或 12.46 万人(95% CI=11.68-13.24)符合 SPRINT 标准,5.78 万人(46.36%)未接受治疗。总体而言,如果实施强化 BP 治疗,美国每年将有 0.07 万人(95% CI=0.06-0.08)死亡,中国每年将有 0.31 万人(95% CI=0.25-0.39)死亡得到预防或推迟,而每年美国和中国将分别发现 12 万和 68 万例低血压病例。
相当一部分中国和美国老年人符合 STEP 和 SPRINT 的入选标准。如果采用强化 BP 治疗,美国和中国每年将分别预防或推迟 7 万和 31 万人死亡。